VLS Valneva SE

Valneva SE - Declaration of voting rights - December 2025

Valneva SE - Declaration of voting rights - December 2025

VALNEVA

Declaration of shares and voting rights

December 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon

Regulated market of Euronext Paris - Compartment B

Declaration date: January 8, 2026

Number of shares

composing the share capital of Valneva
Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



 



173,539,745



ordinary shares with a par value of €0.15 each
189,428,384Double voting rights granted on 3,412 ordinary shares



 



Transfer into bearer form of 4,895 shares with double voting rights



 



Exercise of stock options resulting in the issuance of 429,317 new ordinary shares



 



Definitive attribution of 255,218 free ordinary shares
Between December 1 & December 27, 2025



 



Between December 1 & December 27, 2025



 



Between December 1 & December 5, 2025



 



 



On December 15, 2025
189,304,062

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
08/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE

Valneva to Meet with Investors during the J.P. Morgan Healthcare Confe...

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference  Saint Herblain (France), January 09, 2026 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, January 12-14, 2026, in San Francisco. Valneva’s CEO Thomas Lingelbach and CFO Peter Bühler will discuss upcoming catalysts from its clinical development pipeline, including the pivotal ...

 PRESS RELEASE

Valneva rencontrera des investisseurs lors de la J.P. Morgan Healthcar...

Valneva rencontrera des investisseurs lors de la J.P. Morgan Healthcare Conference Saint Herblain (France), le 9 janvier 2026 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que des membres de son équipe dirigeante rencontreront les actionnaires actuels de la Société et des investisseurs institutionnels spécialistes du secteur de la santé du 12 au 14 janvier 2026 lors de la 44e « J.P. Morgan Healthcare Conference » à San Francisco. Le directeur général de Valneva, Thomas Lingelbach, et son directeur financier, Peter Bühler, discuteront de...

 PRESS RELEASE

Valneva SE - Declaration of voting rights - December 2025

Valneva SE - Declaration of voting rights - December 2025 VALNEVA Declaration of shares and voting rights December 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon Regulated market of Euronext Paris - Compartment B Declaration date: January 8, 2026 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recogniz...

 PRESS RELEASE

Déclaration d'actions et de droits de vote de la société Valneva SE - ...

Déclaration d'actions et de droits de vote de la société Valneva SE - décembre 2025 VALNEVA Déclaration d’actions et de droits de vote 31 décembre 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 LyonMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 8 janvier 2026 Nombre d’actions composant le capital de ValnevaNombre total de droits de vote incluant les droits de vote suspendus*Origine de la var...

 PRESS RELEASE

Valneva and Serum Institute of India Announce Discontinuation of Chiku...

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement Saint-Herblain (France), Pune, (India), December 31, 2025 – (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine. Valneva´s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accele...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch